Holen Sie sich die Stockscreener-App
4.61
7.62%
-0.38
Handel nachbörslich:
4.61
Schlusskurs vom Vortag:
$4.99
Offen:
$5.098
24-Stunden-Volumen:
1.60M
Relative Volume:
1.98
Marktkapitalisierung:
$316.84M
Einnahmen:
$46.02M
Nettoeinkommen (Verlust:
$-70.80M
KGV:
-2.533
EPS:
-1.82
Netto-Cashflow:
$-1.61M
1W Leistung:
-20.93%
1M Leistung:
-24.18%
6M Leistung:
-46.58%
1J Leistung:
-77.12%
1-Tages-Spanne:
$4.507
$5.098
1-Wochen-Bereich:
$4.507
$5.71
52-Wochen-Spanne:
$4.507
$23.64
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Firmenname
Eyepoint Pharmaceuticals Inc
Sektor
Branche
Telefon
617-926-5000
Adresse
480 PLEASANT STREET, WATERTOWN, MA
Vergleichen Sie EYPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
4.61 | 316.84M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-07 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-22 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Mizuho | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2021-01-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Fortgesetzt | Laidlaw | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Eyepoint Pharmaceuticals Inc Aktie (EYPT) Neueste Nachrichten
EyePoint Pharmaceuticals at RBC Conference: Insights on Duravu’s Promise By Investing.com - Investing.com UK
Working At Eyepoint - EyePoint Pharmaceuticals
Here's Why We're Watching EyePoint Pharmaceuticals' (NASDAQ:EYPT) Cash Burn Situation - Yahoo Finance
Long Term Trading Analysis for (EYPT) - news.stocktradersdaily.com
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of “Buy” from Analysts - Defense World
EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - The Manila Times
EyePoint's CEO Takes Center Stage: Key Updates Coming at RBC Ophthalmology Conference - Stock Titan
What is Chardan Capital’s Estimate for EYPT FY2026 Earnings? - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Bought by Bank of New York Mellon Corp - Defense World
3 US Healthcare Stocks That Might Be Undervalued 2025 - Value The Markets
(EYPT) Investment Report - news.stocktradersdaily.com
Mizuho maintains EyePoint stock Outperform with $30 target By Investing.com - Investing.com Australia
Mizuho maintains EyePoint stock Outperform with $30 target - Investing.com India
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga India
StockNews.com Upgrades EyePoint Pharmaceuticals (NASDAQ:EYPT) to “Sell” - Defense World
EyePoint Pharmaceuticals at Leerink’s Conference: DuraView’s Promising Potential By Investing.com - Investing.com Canada
Q1 EPS Estimate for EyePoint Pharmaceuticals Cut by Analyst - Defense World
Research Analysts Set Expectations for EYPT FY2025 Earnings - Defense World
EyePoint Pharmaceuticals Inc (EYPT) Reports Q3 2023 Financial Re - GuruFocus.com
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Full-Year Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
Rhumbline Advisers Purchases 12,443 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Chardan Capital Reiterates “Buy” Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World
HC Wainwright Reaffirms Buy Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT) - Defense World
Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews - Benzinga
EyePoint Pharmaceuticals: Promising Clinical Progress and Strong Financial Position Justify Buy Rating - TipRanks
H.C. Wainwright maintains EyePoint stock Buy rating, $22 target - Investing.com India
H.C. Wainwright maintains EyePoint stock Buy rating, $22 target By Investing.com - Investing.com South Africa
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2024 Earnings Call Transcript - Insider Monkey
Despite Recent Gains, EyePoint Pharmaceuticals Insiders Are Still Down US$32k - Yahoo Finance
EyePoint Pharmaceuticals: Q4 Earnings Snapshot - Midland Daily News
EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highli - GuruFocus.com
EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ... - Yahoo Finance
EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ... By GuruFocus - Investing.com Canada
EyePoint Pharmaceuticals Reports 2024 Financial Results - TipRanks
EyePoint Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Earnings call transcript: EyePoint Pharmaceuticals Q4 2024 results show revenue beat, EPS miss - Investing.com India
Earnings call transcript: EyePoint Pharmaceuticals Q4 2024 results show revenue beat, EPS miss By Investing.com - Investing.com South Africa
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
EyePoint Pharmaceuticals Q4 2024 Earnings: Revenue Beats at $11. - GuruFocus.com
EYEPOINT PHARMACEUTICALS Earnings Results: $EYPT Reports Quarterly Earnings - Nasdaq
EyePoint Pharmaceuticals shares jump nearly 5% on revenue beat By Investing.com - Investing.com Australia
EyePoint Pharmaceuticals shares jump nearly 5% on revenue beat - Investing.com
EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments - The Manila Times
EyePoint Pharmaceuticals, Inc. Q4 Loss Increases, Misses Estimates - Nasdaq
EyePoint Reports Mixed Earnings: Can Its $371M War Chest and Promising Eye Disease Pipeline Deliver Returns? - StockTitan
EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times
Earnings To Watch: EyePoint Pharmaceuticals Inc (EYPT) Reports Q4 2024 Result - Yahoo Finance
Eyepoint Announces Participation At Upcoming Investor Conferences - MENAFN.COM
EyePoint Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Nasdaq
Finanzdaten der Eyepoint Pharmaceuticals Inc-Aktie (EYPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):